Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.56 |
| ▸ | HTR7 | P34969 | 11/20 | 0.47 |
| ▸ | HTR1A | P08908 | 10/20 | 0.47 |
| ▸ | HTR2B | P41595 | 10/20 | 0.47 |
| ▸ | HTR6 | P50406 | 10/20 | 0.47 |
| ▸ | HTR3A | P46098 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR5A | P47898 | 3/20 | 0.44 |
| ▸ | HTR1D | P28221 | 5/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13344890 | 0.80 | TTR (0.44) | HTR7HTR1AHTR2BHTR6HTR3A | |
| SCHEMBL3938908 | 0.76 | NPC1 (0.54) | HTR3APOLBPTPN11 | |
| SCHEMBL4909469 | 0.75 | HTR7 (0.58) | HTR7HTR1AHTR2BHTR6HTR3A | |
| SCHEMBL8226159 | 0.74 | HTR7 (0.43) | HTR7HTR1AHTR2BHTR6HTR3A | |
| SCHEMBL8226475 | 0.74 | HTR7 (0.43) | HTR7HTR1AHTR2BHTR6KCNH2 | |
| SCHEMBL4912614 | 0.74 | CYP1A2 (0.55) | HTR7HTR1AHTR2BHTR6HTR2A | |
| SCHEMBL15327070 | 0.73 | NOTUM (1.00) | NOTUMPOLBPTPN11 | |
| SCHEMBL29639915 | 0.73 | KCNH2 (0.43) | HTR7HTR1AHTR2BHTR6HTR3A | |
| SCHEMBL8226116 | 0.73 | KCNH2 (0.43) | HTR7HTR1AHTR2BHTR6HTR3A | |
| SCHEMBL5280641 | 0.72 | KDR (0.53) | HTR7HTR1AHTR2BHTR6HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | NOTUM 4686/4885HTR7 36/4885HTR1A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.